The U.S. Food and Drug Administration approved the sunscreen chemical bemotrizinol in May 2026 [3].
This approval marks a significant shift in skin protection availability in the U.S. because it is the first time in over 25 years [1] that the agency has authorized a new active sunscreen ingredient.
Bemotrizinol has been used in Europe and Asia for decades [2]. According to reports, the ingredient provides broad and long-lasting protection against both UVA and UVB rays [2]. Despite its established use in international markets, the chemical remained unavailable in the U.S. until the recent sign-off, which occurred on a Tuesday in May 2026 [3].
Medical professionals said the delay was rooted in regulatory hurdles rather than a lack of efficacy. Dr. Céline Gounder said the ingredient took so long because the FDA requires extensive safety data that had not been submitted for the U.S. market [4].
"It's the first time in over 25 years that the FDA has approved a new sunscreen ingredient," a CBS News medical correspondent said [1].
The gap in approvals highlights the rigorous safety-data requirements mandated by the FDA. While other regions accepted the existing international data, the U.S. regulator required specific testing and documentation before granting authorization [4]. This process ensured the ingredient met domestic safety standards before it could be added to commercial products sold within the country.
“It's the first time in over 25 years that the FDA has approved a new sunscreen ingredient.”
The approval of bemotrizinol suggests a potential opening for other internationally recognized sunscreen filters to enter the U.S. market. For decades, U.S. consumers had access to fewer active ingredients than those in Europe or Asia, often leading to products that were less photostable or more irritating. This move may signal a recalibration of how the FDA evaluates existing international safety data against the need for U.S.-specific clinical trials.
